Search research articles
Contact Us
Filters
Showing results (21-30 of 59) with videos related to
Page
of 6
Sort By:
Journal of the International AIDS Society
|
November 15, 2014
Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
Martin Fisher, Cheryl McDonald, Graeme Moyle, et al.
Open Forum Infectious Diseases
|
November 3, 2025
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline
Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
Journal of Virology
|
August 15, 2014
Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies
Claire Vandergeeten, Rémi Fromentin, Esther Merlini, et al.
AIDS Research and Treatment
|
July 30, 2020
Real-World Experience with Dolutegravir-Based Two-Drug Regimens
Douglas Ward, Moti Ramgopal, David J Riedel, et al.
Open Forum Infectious Diseases
|
May 2, 2022
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study
Steven E Coutre, Christopher Barnett, Olayemi Osiyemi, et al.
Molecular & Cellular Proteomics : MCP
|
February 14, 2021
New Proteomic Signatures to Distinguish Between Zika and Dengue Infections
Kristina Allgoewer, Shuvadeep Maity, Alice Zhao, et al.
HIV Clinical Trials
|
December 1, 2014
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment
Cheryl K McDonald, Claudia Martorell, Moti Ramgopal, et al.
HIV Medicine
|
May 28, 2025
Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis
Ishfaq Rashid, Nathan R Unger, Connor Willis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 26, 2024
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)
Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
AIDS Research and Therapy
|
April 8, 2025
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Eric S Daar, Chloe Orkin, Paul E Sax, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 59) with videos related to
Sort By:
Page
of 6
Journal of the International AIDS Society
|
November 15, 2014
Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
Martin Fisher, Cheryl McDonald, Graeme Moyle, et al.
Open Forum Infectious Diseases
|
November 3, 2025
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline
Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
Journal of Virology
|
August 15, 2014
Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies
Claire Vandergeeten, Rémi Fromentin, Esther Merlini, et al.
AIDS Research and Treatment
|
July 30, 2020
Real-World Experience with Dolutegravir-Based Two-Drug Regimens
Douglas Ward, Moti Ramgopal, David J Riedel, et al.
Open Forum Infectious Diseases
|
May 2, 2022
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study
Steven E Coutre, Christopher Barnett, Olayemi Osiyemi, et al.
Molecular & Cellular Proteomics : MCP
|
February 14, 2021
New Proteomic Signatures to Distinguish Between Zika and Dengue Infections
Kristina Allgoewer, Shuvadeep Maity, Alice Zhao, et al.
HIV Clinical Trials
|
December 1, 2014
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment
Cheryl K McDonald, Claudia Martorell, Moti Ramgopal, et al.
HIV Medicine
|
May 28, 2025
Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis
Ishfaq Rashid, Nathan R Unger, Connor Willis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 26, 2024
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)
Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
AIDS Research and Therapy
|
April 8, 2025
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Eric S Daar, Chloe Orkin, Paul E Sax, et al.
Page
of 6